Targeting KIT for Treatment Of Advanced Melanoma
نویسنده
چکیده
This is a remarkable time for melanoma research and treatment. Before this year, approved agents available for the treatment of metastatic melanoma were limited to dacarbazine (DTIC) and interleukin-2 (IL-2), with benefits achieved in only a small minority of patients treated with either drug. In 2011, however, two new agents, ipilimumab (YervoyTM) and vemurafenib (ZelborafTM), were approved, with each showing a demonstrable survival advantage in patients with advanced disease.
منابع مشابه
Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations has resulted in new specific treatment options. These include vemurafenib, dabrafenib, trametinib, imatinib and other kinase inhibitors t...
متن کاملNew therapies in the treatment of melanoma.
INTRODUCTION Therapies targeting immune checkpoints (CTLA-4) and the MAP kinase signaling pathway (RAS/RAF/MEK/ERK) have transformed the treatment of advanced melanoma in the past year. Agents aimed at other therapeutic targets of interest are being actively evaluated in the clinic. AREAS COVERED Areas of active therapeutic interest in melanoma include immunotherapy, molecularly targeted ther...
متن کاملCase report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
Malignant melanoma is one kind of malignant disease which has high rates of mortality, metastasis, and poor prognosis. The therapeutic landscape is rapidly changing with the development of novel agents in recent decades, such as anti-PD-1 agents, anti-CTLA-4 agents, and BRAF inhibitors. However, since most of these novel agents are very expensive, not all patients can afford them. Apatinib is a...
متن کاملComparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa
Background: Melanoma causes the greatest morbidity and mortality of all skin cancers. Mucosal melanoma is a rare but highly aggressive neoplasm. According to previous studies the prevalence of KIT mutations in acrallentiginous and mucosal melanomas is relatively low (less than 15–20%), but it can have profound therapeutic implications for localized high risk or metastatic diseases. Our goal w...
متن کاملImatinib targeting of KIT-mutant oncoprotein in melanoma.
PURPOSE Melanoma subtypes based on anatomic location and UV light exposure can be further classified based on genetic alterations recently identified. Mutations and gene amplification in KIT have been described in a significant percentage of mucosal and acral melanomas. We recently reported a patient with metastatic mucosal melanoma harboring a known KIT mutation treated with imatinib mesylate ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011